FOXO3's Third Longevity Signal — The NKX3 Repressor Variant
FOXO3 is one of only two genes replicated for longevity associations across every human population tested—the other is APOE. Within FOXO3's vast 101,625 base-pair second intron, several variants independently contribute to exceptional lifespan. rs2764264 is the third major longevity signal in this region, alongside rs2802292 and rs13217795, and has been replicated across Japanese, Italian, German, Chinese, and Northern European populations.
The original 2008 discovery | Willcox BJ et al. FOXO3A genotype is strongly associated with human longevity. Proc Natl Acad Sci USA. 2008
identified rs2764264, rs2802292, and rs13217795 together as longevity variants in Japanese American men. Subsequent meta-analysis and centenarian studies have confirmed each variant carries independent statistical weight, though their effects are partially correlated through a shared haplotype.
The Mechanism
rs2764264 sits in FOXO3 intron 2 and operates through a distinct mechanism from its better-studied neighbors. While rs2802292 creates an HSF1 activator binding site that upregulates FOXO3 during cellular stress,
rs2764264 is predicted (by computational transcription factor binding site analysis) to disrupt an NKX3 transcription factor binding site
. NKX3-1 is a homeobox protein involved in controlling cell proliferation and differentiation. When NKX3 can bind—which occurs in individuals with the T allele—it likely functions as a transcriptional repressor at this intronic element. The protective C allele abolishes this binding site, removing a brake on FOXO3 expression.
The result is complementary but mechanistically distinct from rs2802292: where rs2802292 adds a stress-activated accelerator, rs2764264 removes a constitutive repressor. Together—and with the broader FOXO3 longevity haplotype—these variants may cooperate to keep FOXO3 expression higher across a wider range of cellular contexts.
No proxies in complete linkage disequilibrium with rs2764264 have been identified, confirming this variant captures an independent regulatory element within the FOXO3 locus.
The Evidence
A meta-analysis of 11 independent case-control studies | Bao J et al. Association between FOXO3A gene polymorphisms and human longevity: a meta-analysis. Asian J Androl. 2014
synthesized 1,959 long-lived cases and 1,621 controls across diverse populations, finding
the C allele significantly associated with longevity (OR = 1.20, 95% CI 1.04–1.37, P = 0.01)
. Crucially, sex-stratified analysis revealed a
male-specific effect: OR = 1.38 (95% CI 1.15–1.66, P = 0.001) in males, with no significant association in females (OR = 0.93, P = 0.508)
, marking rs2764264 as a male-enriched longevity signal.
Analysis across four major centenarian cohorts | Bae H et al. Effects of FOXO3 Polymorphisms on Survival to Extreme Longevity in Four Centenarian Studies. J Gerontol A Biol Sci Med Sci. 2018
confirmed the effect in independent datasets, with the C allele showing
coded allele frequency of 0.47 in extreme survivors versus 0.37 in controls
(β = 0.15, SE = 0.042, P = 4.15×10⁻⁴). The Southern Italian cohort showed the strongest signal (β = 0.46, P = 0.0019).
The practical significance becomes especially clear in men with age-related disease.
A prospective study in 3,584 elderly Japanese American men (1991–2019) | Chen R et al. FOXO3 longevity genotype mitigates the increased mortality risk in men with a cardiometabolic disease. Aging. 2020
found that the FOXO3 longevity haplotype—including rs2764264—conferred
HR = 0.81 (95% CI 0.72–0.91, P = 0.0002) for all-cause mortality in men with cardiometabolic disease (diabetes, hypertension, or coronary heart disease)
. Most remarkably, men with cardiometabolic disease who carried the longevity haplotype had essentially identical survival to men without any cardiometabolic disease—the genetic variants fully offset the excess mortality risk of these conditions.
Practical Implications
The male specificity of rs2764264's longevity association distinguishes it from rs2802292, whose protective effects appear in both sexes. Men carrying the T allele lack the NKX3-site disruption that removes constitutive repression of FOXO3, and therefore may have modestly lower FOXO3 expression in resting (non-stressed) cellular conditions.
FOXO3 expression is highly modifiable through lifestyle. Intermittent fasting, high-intensity exercise, caloric restriction, and cold exposure all activate FOXO3 pathways. These interventions may be particularly valuable for TT men, compensating for the lower baseline FOXO3 drive associated with the intact NKX3 binding site. The cardiometabolic disease data suggests that metabolic health is the domain where this variant's effects are most consequential—making metabolic monitoring and early intervention especially important for TT men who develop diabetes, hypertension, or coronary disease.
Interactions
rs2764264 is part of a longevity haplotype in FOXO3 intron 2 alongside rs2802292, rs13217795, and rs2802288. While these variants are correlated (particularly in East Asian populations), rs2764264 is unique in having no variant in complete LD, meaning it captures regulatory information not fully tagged by any of its neighbors. The NKX3-site mechanism is distinct from the HSF1-activator mechanism of rs2802292 and from the isoform-splicing mechanism of rs13217795, suggesting these three variants affect FOXO3 expression through complementary pathways.
For men who carry the TT genotype at both rs2764264 and rs2802292, the combined reduction in FOXO3 regulatory capacity may be greater than either variant alone—a potential compound interaction that warrants study.
All genotypes
Both NKX3 repressor sites intact — standard FOXO3 regulation at this locus
You carry two copies of the T allele, preserving the NKX3 transcription factor binding site in both copies of your FOXO3 gene. About 40% of people of European descent share this genotype. The NKX3 protein can bind at this intronic position, providing constitutive repression that the C allele carriers lack. This represents the non-longevity-enriched FOXO3 regulatory state at this particular position.
Maximal protection — both NKX3 repressor sites disrupted
You carry two copies of the longevity-associated C allele, which disrupts the NKX3 binding site in both copies of your FOXO3 gene. This removes constitutive transcriptional repression at this intronic element, contributing to higher baseline FOXO3 expression. About 14% of people of European descent share this genotype, rising to higher proportions in people with African ancestry (where the C allele is common). Studies in centenarian cohorts show C allele carriers have 16–20% higher odds of exceptional longevity per allele.
One disrupted NKX3 site — meaningful but intermediate FOXO3 boost
You carry one copy of the protective C allele and one T allele, giving you intermediate FOXO3 expression at this intronic regulatory site. About 46% of people of European descent share this genotype. The meta-analysis combined C allele carriers show OR = 1.20 for longevity and HR = 0.81 for mortality in men with cardiometabolic disease, with the heterozygous state capturing much of this benefit.